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Bee venom (BV), which is extracted from honeybees, is used in traditional Korean medical therapy. Several groups have
demonstrated the anti-inﬂammatory eﬀects of BV in osteoarthritis both in vivo and in vitro. Glutamate is the predominant
excitatory neurotransmitter in the central nervous system (CNS). Changes in glutamate release and uptake due to alterations
in the activity of glutamate transporters have been reported in many neurodegenerative diseases, including Parkinson’s disease,
Alzheimer’s disease, and amyotrophic lateral sclerosis. To assess if BV can prevent glutamate-mediated neurotoxicity, we examined
cell viability and signal transduction in glutamate-treated neuronal and microglial cells in the presence and absence of BV. We
induced glutamatergic toxicity in neuronal cells and microglial cells and found that BV protected against cell death. Furthermore,
BV signiﬁcantly inhibited the cellular toxicity of glutamate, and pretreatment with BV altered MAP kinase activation (e.g., JNK,
ERK, and p38) following exposure to glutamate. These ﬁndings suggest that treatment with BV may be helpful in reducing
glutamatergic cell toxicity in neurodegenerative diseases.
1.Introduction
Glutamate is well known as the main excitatory neurotrans-
mitter in the central nervous system (CNS), where it plays
an important role in brain functions including memory,
synaptic plasticity, learning, and cognition. Excitotoxicity is
caused by the excessive and dysregulated activation of gluta-
mate receptors [1]. Overstimulation of NMDA receptors by
glutamatemayunderlietheabnormalneuronaldegeneration
observed following hypoxia, ischemia, hypoglycemia, and
seizures [2].
Glutamate neurotoxicity is known to be associated with
numerous neurodegenerative disorders, including Alzheim-
er’s disease (AD), and it is considered to be a key factor in
the pathogenesis of the disease [3]. Some studies have shown
that amyloid-β protein (Aβ) inhibits glutamate uptake and
leads to an increase in extracellular levels of glutamate [4]. It
has also been reported that Aβ enhances glutamate-induced
by excitotoxicity [5], suggesting that the neurotransmitter
might mediate Aβ-induced cytotoxicity. In vitro,g l u t a m a t e
induces diﬀerent types of cell death, including apoptosis
and necrosis [6]. Recently, microglia have been linked to
glutamate metabolism. Activated microglia from mice or
macaques have been shown to express the excitatory amino
acid transporter genes EAAT-1 and -2, suggesting that, simi-
lar to astrocytes, microglia take up glutamate and metabolize
it to glutamine. Gras and colleagues have suggested that the
clearance of extracellular glutamate and the synthesis of glu-
tamine contribute to the neuroprotective properties of mi-
croglia in HIV-infected individuals [7].
In fact, motor neuron death may be mediated by nu-
merous toxic factors that originate from diﬀerent cell types.
Among these factors, a role for the dysregulation of glu-
tamate homeostasis in amyotrophic lateral sclerosis- (ALS)-
mediated neurodegeneration has been established. In ALS
patients, increased plasma levels of glutamate [8, 9], de-
creased glutamate uptake, decreased expression levels of the
glialglutamatetransporterEAAT2[10,11],andalteredlevels
of glutamine synthetase [12]h a v eb e e nd o c u m e n t e d .
Bee venom (BV) is a traditional Korean medicine that
has been successfully used to treat immune-related diseases,
especially rheumatoid arthritis [13]. BV contains several
biologically active peptides, including melittin, apamin, ado-
lapin,andmastcelldegranulatingpeptide[4].Recentreports2 Evidence-Based Complementary and Alternative Medicine
have indicated that acupuncture and the administration of
BV can impart a signiﬁcant antiarthritic response that is
mediated by the inhibition of inﬂammatory mediators, sim-
ilar to nonsteroidal anti-inﬂammatory drugs [14–16]. Jang
and colleagues have shown that BV has anti-inﬂammatory
eﬀects on the Raw264.7 macrophage cell line that can be
ascribed to the transcriptional downregulation of inducible
nitric oxide synthase (iNOS), Cyclooxygenase-2 (COX-2),
nuclear factor kappa B (NF-κB) and mitogen-activated
protein kinases (MAPKs) [17], and an antibacterial eﬀect
that has no side eﬀects in animal models [18].
In this study, we report that pretreatment of neuronal
and microglial cells with BV signiﬁcantly inhibited glu-
tamate-mediated toxicity. The glutamate-mediated toxicity
required the c-Jun N-terminal kinase (JNK), extracellu-
lar signal-regulated kinase (ERK), p38, and alpha serine/
threonine-protein kinase 1 (AKT) signaling pathways. In
addition, pretreatment with BV signiﬁcantly inhibited the
expression of JNK, ERK, and p38 in glutamate-stimulated
N2a neuronal cells.
The present results may have clinical implications and
suggest that BV may be a potential treatment for the pre-
vention of inﬂammatory or neurodegenerative diseases such
as ALS.
2.MaterialsandMethods
2.1. Materials. BV, Tween-20, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), and L-glutamate
were purchased from Sigma (St. Louis, Mo, USA). Fetal
bovine serum was purchased from Gibco (Grand Island, NY,
USA). The lactate dehydrogenase (LDH) kit was purchased
from Biovision Research Products (Biovision, Calif, USA).
Primary antibodies speciﬁc for p-JNK, JNK, AKT, p-
ERK, ERK, p-p38, and p38 were obtained from Cell Sig-
naling Technology (San Francisco, Calif, USA). The prima-
ry antibody against p-AKT was obtained from Epitomics
(Burlingame, Calif, USA).
2.2. Cell Culture. The N2a neuroblastoma cell line was
purchased from ATCC (Manassas, Va, USA) and grown in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% FBS, 100U/mL penicillin, and 100μg/mL
streptomycin at 37◦Ci na na t m o s p h e r eo f5 %C O 2 in air,
as recommended by the ATCC. Cells were subcultured to a
fresh culture dish when growth reached 70–90% conﬂuence
(i.e., every 2-3 days) as recommended by ATCC. For all
experiments, proliferation state N2a neuroblastoma cells of
passage number 20 or below were used.
The immortalized BV2 murine microglial cell line was
provided by Dr. Sang-Myun Park (Aju University, Republic
Korea) and cultured as described above.
In all experiments, cells were incubated in the presence
or absence of the indicated concentrations of BV before the
addition of glutamate to the culture media.
2.3. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
Bromide (MTT) Assay. This assay is based on the ability of
active mitochondrial dehydrogenase to convert dissolved
MTT into water-insoluble purple formazan crystals. Neu-
r o n a la n dm i c r o g l i a lc e l l sw e r ep l a t e di n9 6 - w e l lp l a t e s
(1 ×104 cells/well). After 24h, the cells were treated with the
indicated concentration of BV for 30min prior to glutamate
treatment for 24h or 72h. The MTT assay was performed as
previously described. Brieﬂy, MTT was added to each well
at a ﬁnal concentration of 0.5mg/mL, and the plates were
incubated for 1h at 37◦C. The culture medium was then
removed, DMSO was added, and the plates were shaken for
10min to solubilize the formazan reaction product. The
absorbance at 570nm was measured using a microplate
reader (xMark, Bio-rad).
2.4. Determination of Membrane Integrity Using an LDH
Release Assay. Cell membrane damage/cytotoxicity was
determined using an LDH release assay, which quantitatively
measures the activity of LDH, a stable cytosolic enzyme that
is released upon cell membrane damage or cell lysis. For this
experiment, neuronal and microglial cells were plated in 96-
well plates (1 ×104 cells/well).Thecellsweretreatedwiththe
indicated concentration of BV for 30min prior to glutamate
treatment for 48h. Culture supernatants were then collected
from each well and assayed for LDH release according to
the manufacturer’s instructions. The absorbance at 450nm
following a 10min reaction was measured by a microplate
reader. The mean change in absorbance in culture super-
natants was calculated for each treatment and is expressed as
thepercentageoftheabsorbanceofcontrolcellsupernatants.
2.5.WesternBlotAnalysis. Followingtreatment,totalcellular
proteins were isolated using ice-cold lysis buﬀer containing
50mM Tris HCl pH 7.4, 1% NP-40, 0.1% SDS, 150mM
NaCl, and the Complete Mini Protease Inhibitor Cocktail
(Roche, Basel, Switzerland). The protein concentration was
determined using a BCA Protein Assay Kit (Pierce, Ill, USA).
Extracted samples (20μg total protein per lane) were sep-
arated using SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and then transferred to nitrocellulose membranes
(Whatman, Kan, USA). The membrane was then incubated
with blocking solution (5% skim milk) to block nonspeciﬁc
protein binding, followed by incubation with the following
primary antibodies: phospho-Akt (pSer473), Akt, phospho-
JNK, JNK, phospho-ERK, ERK, phospho-p38, p38, and α-
tubulin (Abcam, Mass, USA). The membrane was incubated
with a horseradish peroxidase- (HRP)-conjugated secondary
antibody for 2h at room temperature, and speciﬁc protein
bands were detected using the SuperSignal West Femto
ChemiluminescentSubstrate(Pierce,Ill,USA)andenhanced
chemiluminescence reagents (Amersham Pharmacia, NJ,
USA).α-tubulin was used as an internal control to normalize
protein loading. Protein bands were detected and analyzed
using an LAS-3000 image analyzer (Fujiﬁlm, Tokyo, Japan).
Quantiﬁcationoftheblottingbandswasperformedusingthe
Multi Gauge V3.0 software program (Fujiﬁlm).
2.6.StatisticalAnalysis. Resultsareexpressedasmean±SEM
values. Statistical evaluations were conducted using the t-
test for comparisons immunoblotting between control andEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀect of BV on glutamate-mediated neurotoxicity in N2a neuronal cells. (a) N2a cells were treated with the indicated
concentrations of glutamate for 24h. Cell viability was assessed using an MTT assay. (b) After seeding, N2a cells were treated with the
indicated concentrations of BV prior to stimulation with 2mM glutamate. The eﬀects of BV on glutamate excitotoxicity were evaluated
using an MTT assay after 24h incubation (b) or 72h incubation (c). The absorbance at 570nm is expressed as the percent of the relative
untreated control cells and is reported as the mean ± S.E.M. of ﬁve independent experiments. The values signiﬁcantly diﬀerent from the
relative controls are indicated with an asterisk. ∗, ∗∗,a n d∗∗∗ indicate P < 0.05, P < 0.005, and P < 0.001, respectively, compared to
untreated cells. # and ## indicate P < 0.05 and P < 0.005, respectively, compared to the corresponding untreated control.
glutamate or BV-treated group. Graphpad Prism version 5
software program was used for all analyses. A value of P <
0.05 was considered signiﬁcant.
DiﬀerencesintheMTTcellviabilityandLDHassayswere
analyzed with two-way ANOVA tests.
3. Results
3.1. Pretreatment with BV Protects against Glutamate-Induced
CellDeathinN2aNeuronalCells. Todeterminewhetherglu-
tamate induces neuronal cell toxicity, we investigated cell
viability following treatment with diﬀerent glutamate con-
centrations(Figure1(a)).Forthisexperiment,N2acellswere
seeded in 96-well plates and treated with glutamate (0.1 to
10mM) for 24h. At low glutamate concentrations (0.1 to
0.5mM), glutamate-induced cell toxicity was not observed;
however, cells treated with high concentrations of glutamate
(1 to 10mM) showed a signiﬁcant, glutamate concentration-
dependent decrease in viability (Figure 1(a)).
In a previous study, we reported that BV-stimulated cell
survival signaling pathways including the ERK and AKT
pathways and reduced neuronal cell death [19]. To investi-
gate whether BV pretreatment protects neuronal cell from
glutamate-induced excitoxicity, N2a neuroblastoma cells
were pretreated with BV (2.5 or 5.0μg/mL) for 1h before
stimulation with 2mM glutamate. As shown in Figure 1(b),
compared with untreated cells, the glutamate-induced cell
toxicity was signiﬁcantly reduced in the presence of BV (Fig-
ure 1(b)). To investigate whether the neuroprotective eﬀect
of BV pretreatment is dependent on glutamate treatment4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀect of BV on glutamate-mediated toxicity in BV2 microglial cells. (a) BV2cells were treated with the indicated concentrations of
glutamate. Cell viability was measured using an MTT assay. (b) BV2 cells were pretreated with 2.5 or 5μg/mL BV for 1h and then stimulated
with 5mM glutamate or vehicle for 24h. An MTT assay was then performed to evaluate cell toxicity. (c) LDH release by BV- or vehicle-
pretreated BV2 cells stimulated with glutamate for 24h or vehicle was quantiﬁed. All values are expressed as the mean ± S.E.M. from ﬁve
independent experiments. ∗∗∗ indicates P < 0.001 compared to untreated cells, and # and ## indicate P < 0.05 and P < 0.005, respectively,
compared to glutamate-treated BV2 cells (Glu).
duration, we incubated N2a cells with 5mM glutamate for
72h after BV (2.5 or 5.0μg/mL) pretreatment for 1h. BV
(2.5 or 5.0μg/mL) pretreatment increased MTT reduction
signiﬁcantly compared to 5mM glutamate-treated N2a cells
(P < 0.05, Figure 1(c)). In addition, we observed that
BV treatment (2.5 or 5.0μg/mL) increased cell viability
compared to untreated N2a cells (Figures 1(b) and 1(c)).
These results suggest that BV treatment at the proper dose
couldattenuateglutamate-inducedneuronalcellexcitoxicity.
3.2. BV Pretreatment Reduces Glutamate-Induced Microglial
Cell Death. Recently, microglia have been linked to gluta-
mate metabolism. In the BV2 microglial cell line, glutamate
induces apoptosis and accumulates in the mitochondria,
resulting in activation of the caspase-dependent apoptosis
cascade [20]. To examine the cell toxicity of glutamate in mi-
croglia, BV2 cells were treated with 0.1 to 10mM glutamate
for24h,andcellviabilitywasmeasuredusingtheMTTassay.
As expected, glutamate induced concentration-dependent
cell toxicity (Figure 2(a)). Next, we pretreated BV2 cells with
2 . 5o r5 μg/mL BV to examine the protective eﬀect of BV
against glutamate-induced toxicity in microglial cells. As
shown in Figure 2(b), while 5mM glutamate decreased BV2
cell viability to 60% of that measured in control cells, cells
pretreated with 2.5μg/mL BV prior to incubation in 5mM
glutamate showed a 20% increase in viability compared to
cells not pretreated with BV. However, pretreatment with
5μg/mL BV did not protect against glutamate-induced
microglial cell death (Figure 2(b)). To conﬁrm this result,Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Continued.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: BV suppresses the activation of glutamate-mediated signaling in N2a neuronal cells. To determine the mechanism by which BV
protects against glutamate-induced cell toxicity, N2a cells were preincubated with 2.5μg/mL BV for 30min prior to treatment with 5mM
glutamate for 30min. (a) Total cell lysates were separated using 10% SDS-PAGE and western blots were performed using antiphospho JNK
or JNK antibodies. (b) Glutamate-induced p38 activation was determined by anti-pp38 antibody. (c) The expression level of phospho-ERK
was investigated with anti-pERK antibody. (d) The expression of phospho-Akt was measured with antiphospho-Akt antibody in N2a cells.
(e) Levels of tubulin were measured to control for protein loading. Immune blots were quantiﬁed with the relative phospho-/nonphospho-
ratio as indicated. ∗, ∗∗,a n d∗∗∗ indicate P < 0.05, P < 0.005, and P < 0.001, respectively, compared to untreated cells. ## indicates
P < 0.005 compared to glutamate-treated N2a cells (Glu). Con: control, BV: BV-treated cell, Glu: glutamate-treated cell, and BV+Glu: BV
pretreated-cells prior to glutamate treatment.
we performed a lactate dehydrogenase release (LDH) assay.
However, we observed that pretreatment with 2.5μg/mL or
5.0μg/mL BV prior to 5mM glutamate reduced LDH release
by approximately ∼30% compared to the 5mM glutamate-
treated BV2 cells (Figure 2(c)). Based on these ﬁndings, the
protective eﬀect of BV could potentially reduce the neu-
roinﬂammatory events related to activated microglial cells.
3.3. BV Pretreatment Reduces the Glutamate-Stimulated
Phosphorylation of JNK, ERK, and p38 and Increases the
ExpressionofActivatedAKTinN2aCells. Toassessthemech-
anism by which BV reduced glutamate-induced toxicity, we
investigated the eﬀects of BV on the ERK, JNK, and p38
signaling pathways. Glutamate-treated N2a cells exhibited a
30% increase in activated JNK compared to untreated or BV-
treated cells (Figure 3(a)). Interestingly, we observed that BV
pretreatment reduced levels of phospho-JNK in N2a cells
preincubatedwith2.5μg/mLBVandthentreatedwith5mM
glutamate (BV+Glu N2a cells) (Figure 3(a)). p38, which is
involved in cell death signaling pathways, was also activated
by glutamate stimulation; however, the activation of p38 was
suppressed in N2a cells preincubated with BV and then
treated with glutamate (BV+Glu N2a cells) (Figure 3(b)).
ERK signaling has been shown to be important in both cell
survival and cell death [21, 22]. In this study, we found a
1.4-fold increase in phospho-ERK levels following glutamate
treatment; following BV pretreatment, glutamate-induced
phospho-ERK levels were reduced 1.2-fold (Figure 3(c)).
The serine/threonine protein kinase Akt/PKB also has a role
in multiple cellular processes including cell proliferation,
apoptosis, and cell death [23]. As shown in Figure 3(d),B V
or glutamate treatment increased Akt phosphorylation at
Ser435 1.2- to 1.3-fold compared to untreated N2a cells,
and the activation of Akt was 1.5-fold greater in N2a cells
preincubated with BV and then treated with glutamate
(BV+Glu N2a cells). These results suggest that BV pre-
treatment suppresses glutamate-mediated activation of cell
death signaling (pJNK, pp38, and pERK) and increases PI3K
signaling pathways (pAkt).
3.4. BV Treatment Suppresses Glutamate-Mediated JNK Acti-
vation in BV2 Cells. BV2 cells are an immortalized murine
microglial cell line. Glutamate-induced excitotoxicity in mi-
croglia can cause neuroinﬂammation in AD and ALS models
[24, 25]. To evaluate the eﬀects of BV on glutamate-induced
cell toxicity in BV2 microglia, we investigated whether BV
pretreatment aﬀects glutamate excitotoxicity in BV2 cells. As
seen in Figure 4(a), we conﬁrmed the activation of JNK in
15–30min, in accordance with the result seen in BV2 cells
(Figure 4(a)). In addition, the glutamate-induced increase
in the expression of phospho-JNK was decreased 1.5-fold by
pretreatmentwith2.5μg/mLBV(Figure4(b)).Furthermore,
incubation with 5mM glutamate increased Akt phosphory-
lation in a time-dependent manner (Figure 4(c)), and pre-
treatment with 2.5μg/mL BV increased the expression of
phospho-Akt in BV2 cells (Figure 4(d)). Taken together,
these results suggest that BV pretreatment could reduce in-
ﬂammatory cell responses resulting from microglial cell-as-
sociated glutamate excitotoxicity.
4. Discussion
Recent reports on neurodegenerative diseases have shown
that alterations in protein kinase expression and activity can
modify the downstream activation of signaling proteins and
trigger neuronal loss. Glutamate is the predominant excita-
tory neurotransmitter in the CNS, and excessive cellular glu-
tamate release has been connected to excitotoxic events in
neurodegenerative diseases. In this study, we determined if
BV regulates cell viability and protein expression in normal
neuronal and microglial cells. We observed dose-dependent
glutamate-mediated toxicity in both N2a neuroblastoma and
BV2 microglial cells. However, BV pretreatment prior to
glutamate stimulation protected the cells from cell death. In
the case of the BV2 cells, we observed diﬀerent results in the
LDH and MTT assays for cell viability, which suggests a BV-
mediated neuroprotective eﬀect against glutamate (Figures
2(b)-2(c)). Because LDH release is proportional to the rate
of pyruvate loss, this parameter may not precisely evaluate
cell viability in neuronal cells.
According to previous reports, glutamate can either
protect neurons against glutamate-mediated excitotoxicity
[26]orinduceapoptosis.KeyplayersinthecellularresponsesEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Glutamate-mediated changes in protein expression in BV2 cells and eﬀects of BV pretreatment. BV2 cells were seeded in 60mm
plates (2 × 106/plate). (a) After a 24-h incubation, BV2 cells were treated for the indicated incubation time with 5mM glutamate. Cell lysates
were analyzed with western blotting with phospho-JNK or JNK antibodies. (b) BV2 cells were treated with 2.5μg/mL BV for 30min prior to
stimulationwith5mMglutamatefor30min.(c)Aftera24-hincubation,BV2cellsweretreatedfortheindicatedincubationtimewith5mM
glutamate. Cell lysates were analyzed with western blotting with phospho-Akt or Akt antibodies. The activation of Akt was calculated based
on the relative phospho-/nonphosphor- ratio as indicated. (d) BV2 cells were treated with 2.5μg/mL BV for 30min prior to stimulation
with 5mM glutamate for 30min. Western blot analysis was performed with phospho-Akt or total Akt antibodies and evaluated based on
activated Akt/Akt ratio. Levels of tubulin were measured to control for protein loading. ∗ indicates P < 0.05 compared to untreated cells,
and ## indicates P < 0.005 compared to the corresponding control.8 Evidence-Based Complementary and Alternative Medicine
tovariousstimuliincludeERK,p38,andJNK[27].Addition-
ally, the Ras-MAPK pathway is involved in various cellular
functions including survival, long-term potentiation, and
synaptic plasticity [28]. However, the role of the MAPK
pathway in neuronal protection is controversial and depends
upon the duration of ERK activation [28]. Several reports
have suggested that the MAPK-ERK1/2 signaling pathway
promotes cell survival through the activation of CREB [23].
Activation of ERK has also been shown to contribute to
neuronal death in some models of neurotoxicity [21, 22].
In this paper, we found that BV inhibited the glutamate-
induced phosphorylation of ERK, p38, and JNK in N2a
neuroblastomacellsandglutamate-inducedJNKphosphory-
lation in BV2 microglial cells. The optimized concentration
of BV (2.5 μg/mL) increased phospho-AKT expression [23].
TheactivationofMAPKs,includingERK,p38,andJNK[29–
32], is promoted by protein kinase C (PKC). Previous studies
havedemonstratedthatERKisinvolvedingrowth-associated
responses and that JNK and p38 are activated by cytotoxic
stresses,includingthecytokine-likelipopolysaccharide(LPS)
[29]. However, other reports have shown that BV increased
the phosphorylation of JNK in Raw 264.7 macrophages and
synoviocytes [33]. We found that, in N2a neuroblastoma
cells, AKT levels were upregulated by treatment with BV and
glutamateandthatBVcombinedwithglutamatestimulation
was the most eﬀective at increasing AKT expression in N2a
neuroblastoma cells. In addition, we observed higher cell
mortality because of glutamate in microglial cells compared
to N2a cells. These results suggest that BV can protect against
glutamatergic damage. In BV2 microglial cells, pretreatment
with BV decreased glutamate-induced JNK upregulation
compared to glutamate-treated cells. We hypothesize that BV
could be eﬀective against cell stress and that it may con-
tribute to cell survival via decreasing JNK protein levels fol-
lowing exposure to increased glutamate concentrations. In
addition, BV pretreatment increased the activation of AKT
in BV2 cells. Furthermore, BV combined with glutamate
treatment modestly upregulated AKT phosphorylation in
BV2 microglial cells. Taken together, our results suggest that
BV-induced AKT activation contributes to cell survival in
both BV2 microglial cells and N2a neuronal cells.
Amyotrophic lateral sclerosis (ALS) is a fatal paralytic
disorder characterized by the selective death of motor neu-
rons. Approximately 10% of ALS cases are inherited (FALS)
and 90% are sporadic (SALS). About 25% of the FALS cases
are caused by missense mutations in the ubiquitously ex-
pressed enzyme Cu2+/Zn2+ superoxide dismutase (SOD1).
Several reports support a role for oxidative stress in neuronal
death during aging and in neurodegenerative diseases (e.g.,
ALS). In addition to reactive oxygen species, glutamate may
also be involved in ALS [34]. Although paralysis in ALS
results from the death of motor neurons, the cellular auton-
omy of ALS pathogenesis has been questioned by studies in
which mutant SOD1 was selectively deleted in microglia and
astrocytes; these studies emphasize the contribution of these
cells to ALS pathogenesis.
To the best of our knowledge, this study is the ﬁrst to
show that BV inhibits cell death and activation of proapop-
totic signaling in glutamate-stimulated cells. We also show
that BV attenuates cell toxicity though inhibition of the JNK
and p38 pathways. These ﬁndings emphasize the clinical
importance of BV for the treatment of glutamate-mediated
syndromes and inﬂammatory diseases. Further investigation
of this activity in vivo is necessary to elaborate the mech-
anisms involved and to permit the full exploitation of the
therapeutic potential of BV. To test the eﬀectiveness of BV
in treating ALS, future studies are needed to elucidate the
signaling responses activated by glutamate or BV in neurons
from mutant hSOD1 transgenic mice. In addition, BV con-
tains a variety of peptides (e.g., melittin and apamin), en-
zymes (e.g., PLA2, histamine, and epinephrine), nonpeptide
components including lipids and carbohydrates, and free
amino acids. Therefore, further research is required to deter-
mine bioactive single element of BV.
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